Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications

doi:10.3748/wjg.v21.i43.12322

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 43

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12890)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

923

WORD

318

HTML

8067

Figures (1-1)

286

Tables (1-3)

252

Sum=9846

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1221

Download

1823

Sum=3044

Nov 21, 2015 (publication date) through Dec 30, 2024

Times Cited of This Article

Times Cited (59)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Nov 21, 2015; 21(43): 12322-12333
Published online Nov 21, 2015. doi: 10.3748/wjg.v21.i43.12322

Open in New Tab Full Size Figure Download Figure

Figure 1 Effects of Rifaximin on gut-liver axis. Rifaximin decreases endotoxemia and inflammation both directly and indirectly, by reducing bacterial translocation, counteracting bacterial overgrowth and modulating gut microbiota composition and function. Due to these peculiar effects, rifaximin is used for the treatment of advanced liver disease complications. HE: Hepatic encephalopathy; SIBO: Small intestinal bacterial overgrowth; SBP: Spontaneous bacterial peritonitis; HRS: Hepatorenal syndrome.

Citation: Ponziani FR, Gerardi V, Pecere S, D’Aversa F, Lopetuso L, Zocco MA, Pompili M, Gasbarrini A. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol 2015; 21(43): 12322-12333
URL: https://www.wjgnet.com/1007-9327/full/v21/i43/12322.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i43.12322